VKVirginija Kalinauskaite-Zukauske

Virginija Kalinauskaite-Zukauske

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginija Kalinauskaite-Zukauske has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comorbidity Burden and Clinical Management Challenges in Severe Asthma: Insights from a Pan-European SHARP Study

    by Saša Rink, Anna Freeman, Aruna T Bansal, Betty Frankemölle, Mehar Singh, Jacob K Sont, Apostolos Bossios, Ben Ainsworth, Michael Hyland, Rekha Chaudhuri, et al.

    Background and Objective: Severe asthma (SA) is commonly complicated by multiple comorbidities, which significantly worsen clinical outcomes. However, the recognition of asthma comorbidities in clinical practice remains unclear. We aimed to assess gaps in comorbidity documentation in SA registries, evaluate comorbidity prevalence and variation across Europe, and explore physician perspectives on multimorbidity management, with a focus on real-world recognition and documentation of comorbidities. Methods: We analysed data from 13,245 SA patients across 22 European registries. Thirty-two clinically relevant comorbidities were grouped into five categories (type 2 (T2)-related, pulmonary, extrapulmonary, psychophysiological, and steroid–related) to assess registry capture and national prevalence. A pan-European online survey of 239 SA specialists explored clinical approaches and resources for multimorbidity management. Results: Across the registries, T2-related and pulmonary comorbidities were captured more consistently than extrapulmonary, psychophysiological, and steroid-related conditions, with substantial variation between countries. The most prevalent recorded comorbidities included chronic sinusitis (40%), nasal polyps (35%), obesity (30%), allergic rhinitis (30%), and gastroesophageal reflux disease (29%) but their prevalence varied widely across countries. Forty-one percent of surveyed physicians lacked multidisciplinary team (MDT) access, with lack of time (36%) and funding (26%) reported as the main barriers. Eighty-five percent of respondents acknowledged the impact of multimorbidity on asthma outcomes and expressed a need for improved training and patient education to improve its management. Conclusion: Comorbidities are highly prevalent in European SA populations but remain inconsistently documented across registries, especially steroid–related conditions. However, these findings should be interpreted in the context of heterogeneity in registry structure, diagnostic pathways, and data capture practices across countries. Limited resources further constrain optimal multimorbidity management. These findings highlight the need for standardized registry protocols, improved MDT access, and targeted education. This study provides the first pan-European evaluation of comorbidity capture in SA registries alongside physician perspectives on multimorbidity.

  • Effects of 24 weeks of benralizumab therapy on serum levels of IL-5, IL-33, GM-CSF, eotaxin, and clinical outcomes in patients with severe eosinophilic asthma

    by Virginija Kalinauskaitė-Žukauskė, Andrius Januškevičius, Jolita Palačionytė, Airidas Rimkūnas, Eglė Vasylė, Dominykas Remeika, KęStutis Malakauskas

    Background: Severe eosinophilic asthma (SEA) is driven by type 2 inflammation, and benralizumab, a monoclonal antibody that targets the interleukin (IL) 5 receptor α, induces eosinophil depletion; however, its effects on circulating inflammatory mediators are still not fully understood. Aim: To evaluate the effects of benralizumab on serum levels of IL-5, IL-33, granulocyte–macrophage colony-stimulating factor (GM-CSF) and eotaxin, and to assess clinical outcomes in patients with SEA. Methods: Ten patients with SEA were evaluated before treatment (V1), 4 (V2), 16 (V3), and 24 weeks (V4) after subcutaneous benralizumab 30 mg. Forced expiratory volume in 1 second (FEV1), fractional exhaled nitric oxide (FeNO), asthma control test (ACT) were assessed. Serum cytokines were measured by enzyme-linked immunosorbent assay. Results: Complete eosinophil depletion occurred after the first dose. Serum IL-5 levels remained unchanged. Eotaxin levels increased early, from 276.0 ± 79.8 (V1) to 530.2 ± 99.2 pg/mL (V2; p=0.005) and remained stably elevated thereafter. In contrast, significant changes in GM-CSF and IL-33 levels were observed starting from V3, with GM-CSF increasing (19.0 ± 4.4 to 23.3 ± 5.7 pg/mL; p=0.007) and IL-33 decreasing (35.8 ± 2.8 to 31.1 ± 5.6 pg/mL; p=0.028). Clinical improvement became evident at V3, with FEV1 increasing from 1.60 ± 0.53 L (58.8 ± 19.6% pred.) to 2.03 ± 0.55 L (75.0 ± 20.9% pred.; p≤0.012), accompanied by an increase in ACT scores from 9.5 ± 3.4 to 17.0 ± 5.6 (p=0.008). FeNO remained unchanged. Conclusion: The observed changes in inflammatory mediator profiles suggest activation of alternative immune pathways (“inflammatory switching”) as a consequence of eosinophil depletion during clinically effective benralizumab treatment in patients with SEA.

  • Open Access

    Effects of Eosinophilopoietins and C-C Chemokines on Chemotaxis, Adhesion, and ROS Production of Blood Eosinophil Subtypes in Asthma Patients

    by Airidas Rimkunas, Andrius Januskevicius, Egle Vasyle, Virginija Kalinauskaite-Zukauske, Jolita Palacionyte, Skaidrius Miliauskas, Kestutis Malakauskas

    Purpose: Two distinct blood eosinophil subtypes have recently been described as inflammatory-like (iEOS-like) and resident-like (rEOS-like) eosinophils. Eosinophilopoietins - interleukin (IL)-3, IL-5, and GM-CSF, as well as C-C chemokines - CCL11, CCL24, and CCL26 (eotaxin-1, 2, 3), CCL5 (RANTES), are key regulators of eosinophil activity. However, our understanding of the effects of these cytokines on blood eosinophil subtype chemotaxis, adhesion, and reactive oxygen species (ROS) production in asthma is limited. Patients and Methods: The study enrolled 13 patients with non-severe allergic asthma (AA), 12 patients with severe eosinophilic asthma (SEA), and 10 healthy subjects (HS). Additionally, AA patients underwent bronchial allergen challenge with D. pteronyssinus, and all scheduled tests were repeated 24 hours later. Ex vivo blood eosinophils were purified using Ficoll gradient centrifugation and magnetic separation, subtyped by CD62L-based magnetic separation, isolating iEOS-like (CD62L−) and rEOS-like (CD62L+) cells. In vitro stimulation of the isolated eosinophils was performed using recombinant human cytokines and chemokines (IL-3, IL-5, GM-CSF; CCL5, 11, 24, 26). Eosinophil chemotaxis was evaluated using Transwell migration assay, adhesion to airway smooth muscle cells (ASMC) by eosinophil peroxidase activity assay, and ROS production measured using a dihydrorhodamine-123 fluorescent probe and flow cytometer. Results: In all groups, IL-3, IL-5, and GM-CSF enhanced iEOS-like cells’ chemotaxis, ROS production, and adhesion to ASMC, with no impact on rEOS-like cell chemotaxis, and only GM-CSF promoted rEOS-like cell adhesion. SEA patients’ rEOS-like cells’ ROS production following activation with eosinophilopoietins was higher compared to the AA group. Allergen-activated AA patients’ blood eosinophil subtypes’ ROS production was further upregulated by IL-3, IL-5, and GM-CSF, p < 0.05, but these cytokines had differential effects on chemotaxis and adhesion to ASMC. In AA and SEA, CCL5, 11, 24 and 26 promoted chemotaxis of blood eosinophil subtypes, p < 0.05. Lastly, CCL26 had a higher effect on iEOS-like cells in AA. Conclusion: Eosinophilopoietins and C-C chemokines increase chemotaxis, adhesion, and ROS production of blood eosinophil subtypes, notably in asthma patients. GM-CSF and CCL26 are the most potent promoters of eosinophil chemotaxis and adhesion, particularly of iEOS-like cells.


  • Open Access

    The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma

    by Airidas Rimkunas, Andrius Januskevicius, Egle Vasyle, Jolita Palacionyte, Virginija Kalinauskaite-Zukauske, Skaidrius Miliauskas, Kestutis Malakauskas

    Purpose: Mepolizumab, which causes a decrease in the number of blood eosinophils, is used to treat patients with severe eosinophilic asthma (SEA). However, there is a relative lack of data on dynamic changes in blood eosinophil subtype distribution and their granule protein expression following anti-interleukin (IL)-5 treatment. Our objective was to evaluate blood inflammatory-like (iEOS-like) and resident-like (rEOS-like) eosinophil subtype distribution and CLC, EDN, EPX, ECP, and MBP gene expression following up to 24 weeks of treatment with mepolizumab in SEA patients. Patients and Methods: Ten free of oral steroids SEA patients and 9 healthy control subjects (HS) were included. Patients were treated with mepolizumab 100 mg subcutaneously/4 weeks, and investigation tests were performed at 0, 4, 12, and 24 weeks. Blood eosinophils were isolated by Ficoll centrifugation and magnetic separation, then subtyped using magnetic separation against CD62L. Gene expression investigation was done using quantitative real time-polymerase chain reaction analysis. Results: Approximately three-quarters of isolated blood eosinophils were iEOS-like cells before mepolizumab treatment, p< 0.01. Blood eosinophil granule protein gene expression was increased in SEA patients compared to the HS, p< 0.05, and iEOS-like cells EPX, MBP, and CLC gene expressions were higher than rEOS-like cells, p< 0.05. Following 4, 12, and 24 weeks of treatment with mepolizumab, residual blood eosinophils shifted towards rEOS-like cells, p< 0.05, and CLC, EPX, ECP, and MBP gene expression of both eosinophil subtypes decreased to HS levels. Conclusion: Treating SEA patients with mepolizumab shifts blood eosinophil subtype distribution towards rEOS-like cells and reduces granule protein gene expression levels to those of healthy individuals.


  • Open Access

    Serum T2-High Inflammation Mediators in Eosinophilic COPD

    by Andrius Januskevicius, Egle Vasyle, Airidas Rimkunas, Jolita Palacionyte, Virginija Kalinauskaite-Zukauske, Kestutis Malakauskas

    Eosinophils are central inflammatory cells in asthma; however, a portion of patients with chronic obstructive pulmonary disease (COPD) have blood or sputum eosinophilia, a condition termed eosinophilic COPD (eCOPD), which may contribute to the progression of the disease. We hypothesize that eosinophilic inflammation in eCOPD patients is related to Type 2 (T2)-high inflammation seen in asthma and that serum mediators might help us to identify T2-high inflammation in patients and choose an appropriate personalized treatment strategy. Thus, we aimed to investigate ten serum levels of T2-high inflammation mediators in eCOPD patients and compare them to severe non-allergic eosinophilic asthma (SNEA) patients. We included 8 subjects with eCOPD, 10 with SNEA, and 11 healthy subjects (HS) as a control group. The concentrations of biomarkers in serum samples were analyzed using an enzyme-linked immunosorbent assay (ELISA). In this study, we found that eCOPD patients were distinguished from SNEA patients by elevated serum levels of sIL-5Rα, MET, TRX1, ICTP, and IL-4, as well as decreased serum levels of eotaxin-1 and sFcεRI. Moreover, MET, ICTP, eotaxin-1, and sFcεRI demonstrated high sensitivity and specificity as potential biomarkers for eCOPD patients. Furthermore, serum levels of IL-5 and IL-25 in combination with sIL-5Rα, MET, and IL-4 demonstrated a high value in identifying T2-high inflammation in eCOPD patients. In conclusion, this study highlights that while T2-high inflammation drives eosinophilic inflammation in both eCOPD and SNEA through similar mechanisms, the distinct expression of its mediators reflects an imbalance between T1 and T2 inflammation pathways in eCOPD patients. A combined analysis of serum mediators may aid in identifying T2-high inflammation in eCOPD patients and in selecting an appropriate personalized treatment strategy.


  • Open Access

    Nintedanibo tyrimų rezultatai įrodė veiksmingumą gydant plataus spektro fibrozuojančias intersticines plaučių ligas

    by Virginija Kalinauskaitė-Žukauskė

    Nintedanibas – tai tirozino kinazės inhibitorius, skiriamas idiopatinei plaučių fibrozei gydyti. Jo veiksmingumas įrodytas klinikiniuose tyrimuose. Vis tik fibrozuojančių intersticinių plaučių ligų yra ir daugiau, tačiau gydymo galimybės ribotos. Kadangi tiek idiopatinės plaučių fibrozės, tiek kitų fibrozuojančių intersticinių plaučių ligų patofiziologiniai procesai turi panašumų, atlikti ikiklinikiniai ir klinikiniai tyrimai parodė, kad nintedanibas gali būti veiksmingas plačiam fibrozuojančių intersticinių plaučių ligų spektrui.

  • Open Access

    SARS–CoV–2 virusas: infekcijos ir vakcinų sukeltas imuninis atsakas

    by Aušrinė Bajoriūnaitė, Virginija Kalinauskaitė-Žukauskė

    SARS–CoV–2 virusas taip pavadintas Tarptautinio virusų taksonomijos komiteto sprendimu dėl savo panašumo į kitus koronavirusus, sukeliančius sunkų kvėpavimo sindromą. 2020 m. vasario mėn. virusas pradėjo sparčiai plisti visame pasaulyje, o 2020 m. kovo 11 d. Pasaulio Sveikatos Organizacija (PSO) paskelbė SARS–CoV–2 viruso sukeliamos ligos – COVID–19 pandemiją. Koronavirusas pažeidžia kvėpavimo sistemą, sukeldamas plaučių uždegimą ir limfopeniją. Viruso struktūros nukleokapsidės ir smaigalio baltymai sukelia šeimininko imuninės sistemos atsaką. Šiuos viruso antigenus atpažįsta ir sunaikina imuninės sistemos humoralinės ir ląstelinės grandies elementai: specifiniai antikūnai ir ląstelės. Vakcinacija yra veiksminga ir saugi profilaktikos priemonė, galinti apsaugoti nuo sunkios COVID–19 ir užkirti kelią jos plitimui.

  • Open Access

    Sunki astma ir COVID-19

    by Virginija Kalinauskaitė-Žukauskė

    Sergančiajam sunkia astma reikalinga specializuota pagalba. Pandemijos akistatoje baiminamasi, kad sunkia astma sergantys asmenys greičiau susirgs COVID–19 arba jos eiga komplikuosis. Atliktų tyrimų duomenys rodo, kad susirgimų arba komplikacijų dažnis nesiskiria nuo bendrosios populiacijos, jei užtikrinama gera astmos simptomų kontrolė ir nėra nuolatinio geriamųjų gliukokortikoidų vartojimo. Daug abejonių būta ir dėl biologinių vaistų skyrimo pandemijos laikotarpiu, tačiau esama patirtis ir atliktų tyrimų duomenys rodo, kad netgi susirgus COVID–19, biologinė terapija turi būti tęsiama, nors pradėti nerekomenduojama. Atskiras daug diskusijų sukėlęs klausimas – vakcinacija. Vis tik kol kas tai vienas veiksmingiausių būdų valdyti pandemijai ir grįžti į kasdienį gyvenimą, buvusį iki pandemijos.

  • Open Access

    Trigubos terapijos, skirtos gydyti sergančiuosius lėtine obstrukcine plaučių liga, itin smulkių vaisto dalelių depozicijos plaučiuose tyrimas

    by Virginija Kalinauskaitė-Žukauskė

    Sergantiesiems lėtine obstrukcine plaučių liga (LOPL) yra nustatyta koreliacija tarp smulkiųjų kvėpavimo takų disfunkcijos ir blogesnių gydymo rezultatų. Todėl svarbu, kad įkvepiamieji vaistai (tiek bronchus plečiantieji, tiek tie, kurie veikia priešuždegimiškai) patektų į smulkiuosius kvėpavimo takus. LOPL palaikomajam gydymui šiuo metu yra patvirtinti du trigubos terapijos vaistai, visus tris komponentus talpinantys viename inhaliatoriuje. Tai yra itin smulkių dalelių beklometa­ zono dipropionatas / formoterolio fumaratas / glikopironio bromidas (BDP / FF / GB) ir ne itin smulkių dalelių flutikazono furoatas / vilanterolis / umeklidinas (FluF / VI / UMEC). Tyrime buvo įvertinta įkvepiamojo gliukokortikoido (IGK), ilgo veikimo β2 agonisto (IVBA) ir ilgo veikimo muskarino receptorių antagonisto (IVMA) depozicija plaučiuose. Vertinimui naudotas funkcinis kvėpavimo takų vaizdavimas (angl. functional respiratory imaging, FRI), pasitelkiant kompiuterinę to­mografiją ir skysčių dinamikos skaičiavimo techniką, kuriai svarbu aerozolio pateikimo sergančiajam savybės, pakartotiniai didelės skiriamosios gebos kompiuterinės tomografijos tyrimai (DSGKT) ir tai, kaip pacientas sukvėpuoja vaistus. Visa tai sudaro sąlygas imituoti vaisto nusėdimą plaučiuose. Į analizę buvo įtraukti 20 LOPL sergančių pacientų, kuriems podilatacinis forsuoto iškvėpimo tūris per pirmą sekundę (FEV1) svyravo nuo 19,3 iki 66,0 proc., DSGKT tyrimų duomenys. Vertinant bendrą vaisto nusėdimą centriniuose ir periferiniuose kvėpavimo takuose procentine dalimi nuo įkvėptos vaisto dozės, nu­statyta, kad IGK depozicija plaučiuose buvo didesnė skiriant BDP / FF / GB, palyginus su FluF / VI / UMEC; vertinant IVBA ir IVMA depoziciją, tiek skiriant vieną, tiek kitą trigubą terapiją, rezultatai buvo panašūs. Visų trijų komponentų depozicija periferiniuose kvėpavimo takuose buvo didesnė skiriant BDP / FF / GB, palyginus su FluF / VI / UMEC. Be to, visų trijų BDP / FF / GB komponentų depozicijos bendrai centriniuose ir periferiniuose kvėpavimo takuose santykiai buvo <1, o tai rododidesnę depoziciją periferiniuose nei centriniuose apatiniuose kvėpavimo takuose. Taigi, visų trijų komponentų (IGK, IVBA ir IVMA) depozicija periferiniuose (smulkiuosiuose) kvėpavimo takuose buvo didesnė skiriant BDP / FF / GB, palyginus su FluF / VI / UMEC (vertinta naudojant funkcinį kvėpavimo takų vaizdavimą, pagrįstą pacientų, sergančių vidutinio sunkumo arba labai sunkia LOPL, profiliais).

  • Open Access

    Asthmatic Eosinophils Promote Contractility and Migration of Airway Smooth Muscle Cells and Pulmonary Fibroblasts In Vitro

    by Ieva Janulaityte, Andrius Januskevicius, Virginija Kalinauskaite-Zukauske, Jolita Palacionyte, Kestutis Malakauskas

    Enhanced contractility and migration of airway smooth muscle cells (ASMC) and pulmonary fibroblasts (PF) are part of airway remodeling in asthma. Eosinophils are the central inflammatory cells that participate in airway inflammation. However, the role of asthmatic eosinophils in ASMC and PF contractility, migration, and differentiation to contractile phenotype has not yet been precisely described. A total of 38 individuals were included in this study: 13 steroid-free non-severe allergic asthma (AA) patients, 11 severe non-allergic eosinophilic asthma (SNEA) patients, and 14 healthy subjects (HS). For AA patients and HS groups, a bronchial allergen challenge with D. pteronyssinus was performed. Individual combined cell cultures were prepared from isolated peripheral blood eosinophils and immortalized ASMC or commercial PF cell lines separately. The migration of ASMC and PF was evaluated using wound healing assay and contractility using collagen gel assay. Gene expression of contractile apparatus proteins, COL1A1, COL5A1, and FN, in ASMC and PF was evaluated using qRT-PCR. We found that contractility and migration of ASMC and PF significantly increased after incubation with asthmatic eosinophils compared to HS eosinophils, p < 0.05, and SNEA eosinophils demonstrated the highest effect on contractility of ASMC and migration of both cell lines, p < 0.05. AA and SNEA eosinophils significantly increased gene expression of contractile apparatus proteins, COL1A1 and FN, in both cell lines, p < 0.05. Furthermore, the allergen-activated AA eosinophils significantly increased the contractility of ASMC, and migration and gene expression in ASMC and PF, p < 0.05. Thus, asthmatic eosinophils change ASMC and PF behavior by increasing their contractility and migration, contributing to airway remodeling.